Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BFLY NASDAQ:DCTH NYSE:ENOV NASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$4.66-3.4%$4.26$1.32▼$5.72$1.19B2.275.84 million shs1.86 million shsDCTHDelcath Systems$11.54+0.0%$9.81$8.12▼$18.23$397.63M0.54416,203 shs107,502 shsENOVEnovis$24.70+2.4%$23.73$21.00▼$37.85$1.42B1.41998,764 shs186,933 shsNVCRNovoCure$16.12+1.5%$12.20$9.82▼$20.06$1.87B0.91.82 million shs359,731 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network-10.66%-6.30%+17.42%+31.34%+118.59%DCTHDelcath Systems+6.76%+9.29%+19.73%+18.87%-3.84%ENOVEnovis+2.23%+2.94%+6.09%+5.65%-29.51%NVCRNovoCure-4.45%+31.02%+50.52%+37.37%-10.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$4.66-3.4%$4.26$1.32▼$5.72$1.19B2.275.84 million shs1.86 million shsDCTHDelcath Systems$11.54+0.0%$9.81$8.12▼$18.23$397.63M0.54416,203 shs107,502 shsENOVEnovis$24.70+2.4%$23.73$21.00▼$37.85$1.42B1.41998,764 shs186,933 shsNVCRNovoCure$16.12+1.5%$12.20$9.82▼$20.06$1.87B0.91.82 million shs359,731 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network-10.66%-6.30%+17.42%+31.34%+118.59%DCTHDelcath Systems+6.76%+9.29%+19.73%+18.87%-3.84%ENOVEnovis+2.23%+2.94%+6.09%+5.65%-29.51%NVCRNovoCure-4.45%+31.02%+50.52%+37.37%-10.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFLYButterfly Network 2.33Hold$5.5619.50% UpsideDCTHDelcath Systems 2.67Moderate Buy$22.5095.06% UpsideENOVEnovis 3.00Buy$47.4392.06% UpsideNVCRNovoCure 2.38Hold$27.2969.26% UpsideCurrent Analyst Ratings BreakdownLatest DCTH, NVCR, ENOV, and BFLY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026NVCRNovoCure Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$13.50 ➝ $17.005/1/2026NVCRNovoCure EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/21/2026NVCRNovoCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026ENOVEnovis William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/16/2026NVCRNovoCure WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.004/10/2026ENOVEnovis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026BFLYButterfly Network Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/18/2026ENOVEnovis Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/4/2026ENOVEnovis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/2/2026BFLYButterfly Network Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.502/27/2026BFLYButterfly Network TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.50 ➝ $6.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFLYButterfly Network$97.61M12.14N/AN/A$0.75 per share6.21DCTHDelcath Systems$85.23M4.66$0.05 per share210.81$3.15 per share3.66ENOVEnovis$2.25B0.63$28.39 per share0.87$26.09 per share0.95NVCRNovoCure$655.35M2.85N/AN/A$2.86 per share5.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFLYButterfly Network-$77.06M-$0.30N/AN/AN/A-73.63%-34.41%-23.91%N/ADCTHDelcath Systems$2.70M$0.07164.84115.35N/A3.17%2.63%2.39%5/7/2026 (Estimated)ENOVEnovis-$1.18B-$20.71N/A6.28N/A-52.69%8.74%4.19%5/7/2026 (Estimated)NVCRNovoCure-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)Latest DCTH, NVCR, ENOV, and BFLY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026DCTHDelcath Systems-$0.0971N/AN/AN/A$23.51 millionN/A5/7/2026Q1 2026ENOVEnovis$0.82N/AN/AN/A$572.02 millionN/A4/30/2026Q1 2026BFLYButterfly Network-$0.04-$0.03+$0.01-$0.05$26.08 million$26.53 million4/30/2026Q1 2026NVCRNovoCure-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million2/26/2026Q4 2025BFLYButterfly Network-$0.04-$0.02+$0.02-$0.06$26.25 million$31.51 million2/26/2026Q4 2025DCTHDelcath Systems-$0.06-$0.05+$0.01-$0.05$20.35 million$20.73 million2/26/2026Q4 2025ENOVEnovis$0.81$0.95+$0.14-$9.10$584.30 million$575.76 million2/26/2026Q4 2025NVCRNovoCure-$0.41-$0.22+$0.19-$0.22$174.40 million$174.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFLYButterfly NetworkN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFLYButterfly NetworkN/A4.023.03DCTHDelcath SystemsN/A10.929.98ENOVEnovis0.852.021.04NVCRNovoCure0.712.902.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFLYButterfly Network37.85%DCTHDelcath Systems61.12%ENOVEnovis98.45%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipBFLYButterfly Network25.18%DCTHDelcath Systems19.36%ENOVEnovis2.90%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFLYButterfly Network460254.63 million190.52 millionOptionableDCTHDelcath Systems6034.46 million27.79 millionOptionableENOVEnovis7,80257.54 million55.87 millionOptionableNVCRNovoCure1,605115.82 million109.43 millionOptionableDCTH, NVCR, ENOV, and BFLY HeadlinesRecent News About These CompaniesHC Wainwright Estimates NovoCure's Q2 Earnings (NASDAQ:NVCR)May 5 at 8:32 AM | marketbeat.comNovoCure (NASDAQ:NVCR) Price Target Raised to $17.00 at Wells Fargo & CompanyMay 4 at 3:27 PM | marketbeat.comStocks with rising relative price strength: NovocureMay 4 at 2:02 PM | msn.comInternational Markets and NovoCure (NVCR): A Deep Dive for InvestorsMay 4 at 10:16 AM | zacks.comNovoCure (NASDAQ:NVCR) Shares Up 6.8% - Here's WhyMay 3 at 4:49 AM | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 2, 2026 | finance.yahoo.comNovoCure (NASDAQ:NVCR) Trading 6.8% Higher - Should You Buy?May 1, 2026 | marketbeat.comNovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer YetMay 1, 2026 | seekingalpha.comNovoCure: Q1 Earnings SnapshotMay 1, 2026 | chron.comNovocure jumps after raising FY26 sales outlook, Q1 revenue beatMay 1, 2026 | seekingalpha.comTwo medical stocks skyrocket after demolishing views — and one is about to break outMay 1, 2026 | msn.comNovoCure (NVCR) Q1 2026 Earnings TranscriptMay 1, 2026 | finance.yahoo.comWhy NovoCure Limited’s (NVCR) Stock Is Up 19.53%May 1, 2026 | aaii.comANovoCure (NASDAQ:NVCR) Announces Earnings ResultsApril 30, 2026 | marketbeat.comNovoCure Limited (NVCR) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comNovoCure (NASDAQ:NVCR) Shares Gap Up - Should You Buy?April 30, 2026 | marketbeat.comNovoCure (NVCR) Reports Q1 Loss, Beats Revenue EstimatesApril 30, 2026 | zacks.comNovoCure Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comNovoCure Limited 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by AnalystsApril 25, 2026 | marketbeat.comNovoCure (NVCR) to Release Quarterly Earnings on ThursdayApril 23, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCTH, NVCR, ENOV, and BFLY Company DescriptionsButterfly Network NYSE:BFLY$4.66 -0.17 (-3.42%) As of 11:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.Delcath Systems NASDAQ:DCTH$11.54 +0.01 (+0.04%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Enovis NYSE:ENOV$24.70 +0.58 (+2.38%) As of 11:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.NovoCure NASDAQ:NVCR$16.12 +0.24 (+1.52%) As of 11:43 AM Eastern This is a fair market value price provided by Massive. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
